Alto Neuroscience Inc. announced plans to accelerate the development of ALTO-207 for treatment-resistant depression following a successful outcome from a recent FDA meeting. The company intends to initiate a Phase 2b, potentially pivotal, clinical trial of ALTO-207 by mid-2026, and a Phase 3 clinical trial by early 2027, pending alignment with the FDA and completion of Phase 3 readiness activities. The advancement is supported by a $50 million private placement. Additionally, Alto provided an update on its pipeline, including positive blinded pharmacokinetic $(PK)$ analysis results from ongoing Phase 2 studies of ALTO-100 in bipolar depression and ALTO-101 in cognitive impairment associated with schizophrenia $(CIAS)$. The company also announced that topline data from the Phase 2 study of ALTO-101 in CIAS are expected to be reported in the first quarter of 2026. Results from current studies have not yet been presented and are anticipated in the future.